CN1771978A - 一种三七三醇皂苷组合物及其制备方法和用途 - Google Patents
一种三七三醇皂苷组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN1771978A CN1771978A CNA2004100906065A CN200410090606A CN1771978A CN 1771978 A CN1771978 A CN 1771978A CN A2004100906065 A CNA2004100906065 A CN A2004100906065A CN 200410090606 A CN200410090606 A CN 200410090606A CN 1771978 A CN1771978 A CN 1771978A
- Authority
- CN
- China
- Prior art keywords
- notoginseng
- saponin
- triol
- ginsenoside
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 104
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 104
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229930182490 saponin Natural products 0.000 claims abstract description 16
- 150000007949 saponins Chemical class 0.000 claims abstract description 16
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims abstract description 12
- 208000005189 Embolism Diseases 0.000 claims abstract description 10
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims abstract description 8
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 91
- 239000000843 powder Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- 238000005325 percolation Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 229930182494 ginsenoside Natural products 0.000 claims description 6
- 229940089161 ginsenoside Drugs 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 5
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract 3
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 abstract 3
- 230000002792 vascular Effects 0.000 abstract 2
- 239000012264 purified product Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 206010008118 cerebral infarction Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 239000012567 medical material Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960000715 nimodipine Drugs 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- -1 triol saponins Chemical class 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000000920 Typhonium flagelliforme Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
实施例编号 | 所用三七药材重量 | 浸泡、渗漉用乙醇的浓度和用量 | 采用树脂、洗脱树脂用乙醇的浓度和用量 | PTS的重量和主要组分的含量 |
实施例2 | 1kg | 浸泡用乙醇浓度为75wt%,用量为2倍药材重量渗漉用乙醇浓度为75wt%,用量为9倍药材重量 | D101(购自天津农药厂)50wt%2倍药材重量 | PTS的重量:0.0735kgRg1:35.01wt%Re:4.445wt%R1:11.56wt% |
实施例3 | 1kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D101(购自天津农药厂)40wt%1.5倍药材重量 | PTS的重量:0.0556kgRg1:60.72wt%Re:7.535wt%R1:12.23wt% |
实施例4 | 1kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D140(购自成都中蓝晨光化工研究院)30wt%1.5倍药材重量 | PTS的重量:0.0184kgRg1:47.415wt%Re:6.505wt%R1:16.15wt% |
Claims (15)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004100906065A CN1771978B (zh) | 2004-11-09 | 2004-11-09 | 一种三七三醇皂苷组合物及其制备方法和用途 |
EP04802573.8A EP1825860B1 (en) | 2004-11-09 | 2004-12-29 | A panaxatriol saponins composition and its preparing method and the use |
PCT/CN2004/001561 WO2006050641A1 (fr) | 2004-11-09 | 2004-12-29 | Composition de panaxatriol saponins ainsi que son utilisation et un procede pour la preparer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004100906065A CN1771978B (zh) | 2004-11-09 | 2004-11-09 | 一种三七三醇皂苷组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1771978A true CN1771978A (zh) | 2006-05-17 |
CN1771978B CN1771978B (zh) | 2011-06-08 |
Family
ID=36336195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004100906065A Active CN1771978B (zh) | 2004-11-09 | 2004-11-09 | 一种三七三醇皂苷组合物及其制备方法和用途 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1825860B1 (zh) |
CN (1) | CN1771978B (zh) |
WO (1) | WO2006050641A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597314B (zh) * | 2008-06-06 | 2012-01-04 | 北京本草天源药物研究院 | 一种人参皂苷Rg1的制备方法 |
CN1869058B (zh) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | 从三七中制备三醇组人参皂苷和二醇组人参皂苷的方法 |
CN1869057B (zh) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | 一种三醇组人参皂苷和二醇组人参皂苷的制备方法 |
WO2012027968A1 (zh) * | 2010-09-02 | 2012-03-08 | 成都华神集团股份有限公司制药厂 | 一种三七三醇皂苷肠溶微丸及其胶囊剂和制备方法 |
CN1869059B (zh) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | 从人参叶中制备人参皂苷单体的方法 |
CN112022863A (zh) * | 2020-09-08 | 2020-12-04 | 成都华神科技集团股份有限公司 | 组合物、三七提取物的制备方法以及三七提取物的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893230B (zh) * | 2012-12-27 | 2016-07-20 | 上海中医药大学附属龙华医院 | 三七花总皂苷在制备促进血管新生的药物中的应用 |
CN108835639A (zh) * | 2018-08-07 | 2018-11-20 | 玉溪市维和维生堂保健食品有限公司 | 一种三七花枝组合物及其制备方法与应用 |
CN109593745B (zh) * | 2019-01-22 | 2022-06-24 | 云南师范大学 | 一种能将三七皂苷R1转化为人参皂苷Rg1的木糖苷酶突变体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067244C (zh) * | 1996-02-17 | 2001-06-20 | 昆明制药股份有限公司 | 三七皂甙粉针剂 |
CN1302811A (zh) * | 2000-01-03 | 2001-07-11 | 广东泰禾生物药业有限公司 | 化合物(i)、提取方法及在制备治疗急性缺血性脑血管病药中的应用 |
US8486464B2 (en) * | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
CN1334267A (zh) * | 2001-06-28 | 2002-02-06 | 中国科学院昆明植物研究所 | 三七总甙的制备方法 |
CN1166679C (zh) * | 2001-10-26 | 2004-09-15 | 香港生物科技研究院 | 从三七生粉提取分离三七皂甙R1、人参皂甙Re、三七素的方法 |
CN1414011A (zh) * | 2002-10-17 | 2003-04-30 | 南开大学 | 三七皂苷的提取方法 |
CN1412162A (zh) * | 2002-11-13 | 2003-04-23 | 吉林省中医中药研究院 | 三七叶中总皂苷提取物的制备方法 |
CN1245415C (zh) * | 2002-12-26 | 2006-03-15 | 天津市阳成高科技天然制品有限公司 | 三七叶皂苷的提取方法 |
CN1329037C (zh) * | 2003-05-07 | 2007-08-01 | 丽珠集团利民制药厂 | 一种三七总皂苷静脉注射液及其生产方法 |
CN1491659A (zh) * | 2003-08-28 | 2004-04-28 | 王景成 | 三七总皂苷粉针及制备方法 |
CN1212122C (zh) * | 2003-09-05 | 2005-07-27 | 云南植物药业有限公司 | 三七总皂苷脂质体及其制剂 |
CN1628685A (zh) * | 2004-09-07 | 2005-06-22 | 张平 | 一种含三七三醇皂苷的药物组合物及其制备方法 |
-
2004
- 2004-11-09 CN CN2004100906065A patent/CN1771978B/zh active Active
- 2004-12-29 EP EP04802573.8A patent/EP1825860B1/en active Active
- 2004-12-29 WO PCT/CN2004/001561 patent/WO2006050641A1/zh active Application Filing
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1869058B (zh) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | 从三七中制备三醇组人参皂苷和二醇组人参皂苷的方法 |
CN1869057B (zh) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | 一种三醇组人参皂苷和二醇组人参皂苷的制备方法 |
CN1869059B (zh) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | 从人参叶中制备人参皂苷单体的方法 |
CN101597314B (zh) * | 2008-06-06 | 2012-01-04 | 北京本草天源药物研究院 | 一种人参皂苷Rg1的制备方法 |
WO2012027968A1 (zh) * | 2010-09-02 | 2012-03-08 | 成都华神集团股份有限公司制药厂 | 一种三七三醇皂苷肠溶微丸及其胶囊剂和制备方法 |
CN102379885A (zh) * | 2010-09-02 | 2012-03-21 | 成都华神集团股份有限公司制药厂 | 一种三七三醇皂苷肠溶微丸及其胶囊剂和制备方法 |
CN112022863A (zh) * | 2020-09-08 | 2020-12-04 | 成都华神科技集团股份有限公司 | 组合物、三七提取物的制备方法以及三七提取物的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1825860A1 (en) | 2007-08-29 |
WO2006050641A1 (fr) | 2006-05-18 |
EP1825860B1 (en) | 2014-07-09 |
EP1825860A4 (en) | 2009-03-11 |
CN1771978B (zh) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100581558C (zh) | 活血止痛胶囊的制备工艺 | |
CN101214270B (zh) | 刺五加有效部位的提取物、其制备方法、其应用 | |
CN1931228A (zh) | 金钱草总黄酮提取物及其制备方法 | |
CN1771978B (zh) | 一种三七三醇皂苷组合物及其制备方法和用途 | |
CN100502880C (zh) | 一种三七二醇皂苷组合物及其制备方法和用途 | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
CN101224246B (zh) | 一种枇杷叶总三萜酸的制备方法及其降血糖功能 | |
CN104510853A (zh) | 一种治疗妇女痛经的中药有效部位组合物及其用途 | |
CN107375430A (zh) | 一种具有防治糖尿病及并发症的姜黄素组合物 | |
CN103800418A (zh) | 一种活血止痛组合物及胶囊制备工艺和应用 | |
CN100479837C (zh) | 治疗缺血性脑血管疾病的药物及其制造方法 | |
CN102670865A (zh) | 红葱的活性成分提取工艺 | |
CN101474315B (zh) | 一种祖师麻的有效组分群及其制备方法和应用 | |
CN101375954B (zh) | 一种药物组合物、其制备方法及用途 | |
CN100502885C (zh) | 一种治疗痛经的药物组合物及其制备方法 | |
CN101073598A (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN1634241A (zh) | 治疗心脑血管疾病的复方三七制剂及其制备方法 | |
CN101926848B (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN102671136A (zh) | 一种治疗肩周炎症的中药制剂及其制备方法 | |
CN110742983B (zh) | 一种用于治疗痛风急性发作的中药制剂及其制备方法 | |
CN102716231A (zh) | 一种治疗脑损伤和脑水肿的中药组合物及其应用 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
CN101185669B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN101380347A (zh) | 杏香兔耳风总黄酮提取物及其提取方法和用途 | |
CN105326879A (zh) | 油菜花粉脂肪酸提取物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060517 Assignee: Chengdu University of Traditional Chinese Medicine Sichuan Huashen pharmaceutical limited liability company Assignor: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Contract record no.: 2013510000111 Denomination of invention: Notoginseng triol-saponin composition and its prepn and use Granted publication date: 20110608 License type: Exclusive License Record date: 20131128 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee after: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory Address before: 610225 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road 2 No. 3 Patentee before: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Document name: Notification of Passing Examination on Formalities |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee after: Pharmaceutical factory of Chengdu Huashen Technology Group Co., Ltd Address before: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee before: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201022 Address after: 611731 No.101, 1st floor, building 2, no.1168 Shuxin Avenue, Chengdu high tech Zone (West District), Sichuan Province Patentee after: Chengdu Huashen Technology Group Co.,Ltd. Address before: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee before: Pharmaceutical factory of Chengdu Huashen Technology Group Co.,Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Chengdu University of Traditional Chinese Medicine Sichuan Huashen pharmaceutical LLC Assignor: PHARMACEUTICAL FACTORY OF CHENGDU HUASUN GROUP Inc.,Ltd. Contract record no.: 2013510000111 Date of cancellation: 20211014 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060517 Assignee: Pharmaceutical factory of Chengdu Huashen Technology Group Co.,Ltd. Assignor: Chengdu Huashen Technology Group Co.,Ltd. Contract record no.: X2021990000757 Denomination of invention: The invention relates to a Panax notoginseng triol saponin composition and a preparation method and application thereof Granted publication date: 20110608 License type: Exclusive License Record date: 20211207 |